Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Dasatinib Fails to Improve Outcomes in CBF-AML

2.

Discovery of estrogen receptor 'switches' may aid breast cancer treatment

3.

Medical debt in collections persists after cancer diagnosis

4.

Childhood cancer survivors face new health problems later in life, study shows

5.

A Lot Can Be Said About You by Including Yourself in Photos.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot